
It has been shown that treatment with zzso zzso zzso zzso zzso improves key clinical features of type I zzso disease after 1 year of zzso This study reports longer-term efficacy and safety zzso Patients who had completed 12 months of treatment with zzso zzso zzso zzso three times zzso were enrolled to continue with therapy in an extension zzso Data are presented up to month zzso Liver and zzso volumes measured by CT or zzso were scheduled every 6 zzso zzso and zzso zzso including zzso activity (a sensitive marker of zzso disease zzso were monitored every 3 zzso Safety data were also collected every 3 zzso zzso of 22 eligible patients at four zzso entered the extension phase and 14 of these completed 36 months of treatment with zzso After 36 months, there were statistically significant improvements in all major efficacy zzso Liver and zzso organ volumes were reduced by zzso and zzso zzso In patients whose zzso value had been below zzso zzso at zzso mean zzso increased progressively from baseline by zzso zzso at month 12 zzso zzso zzso at month 24 zzso zzso and zzso zzso at month 36 zzso zzso The mean zzso count at month 36 increased from baseline by 22 zzso zzso No new cases of peripheral zzso occurred since previously zzso zzso and weight loss, which were frequently reported during the initial 12-month study, decreased in magnitude and prevalence during the second and third zzso Patients treated with zzso for 3 years show significant improvements in organ volumes and zzso zzso In conclusion, zzso was increasingly effective over time and showed acceptable zzso in patients who continued with treatment for 3 zzso 

